title: Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer.
authors.forename: Filippo
authors.initials: F
authors.lastname: Bellati
authors.forename: Bellati
authors.initials: B
authors.lastname: Filippo
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Gasparri
authors.forename: Gasparri Maria
authors.initials: GM
authors.lastname: Luisa
authors.forename: Jlenia
authors.initials: J
authors.lastname: Caccetta
authors.forename: Caccetta
authors.initials: C
authors.lastname: Jlenia
authors.forename: Innocenza
authors.initials: I
authors.lastname: Palaia
authors.forename: Palaia
authors.initials: P
authors.lastname: Innocenza
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Benedetti panici
authors.forename: Benedetti Panici
authors.initials: BP
authors.lastname: Pierluigi
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*